Dystrophin (DMD) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Dystrophin is a cytoplasmic protein, which anchors the extracellular matrix to the cytoskeleton via F-actin. It acts as ligand for dystroglycan. It also acts as component of the dystrophin-associated glycoprotein complex which accumulates at the neuromuscular junction and at a variety of synapses in the peripheral and central nervous systems and has a structural function in stabilizing the sarcolemma.
The Dystrophin – Drugs in Development research report provides a comprehensive overview on the therapeutics under development for Dystrophin, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dystrophin and features dormant and discontinued projects.
Key Therapy Areas in the Dystrophin Pipeline Drugs Market
In the Dystrophin pipeline drugs market the key therapy areas are Genetic Disorders, and Musculoskeletal Disorders.
Dystrophin Pipeline Drugs Market, by Therapy Areas
For more therapy area insights, download a free report sample
Key MoA in the Dystrophin Pipeline Drugs Market
In the Dystrophin pipeline drugs market the key MoA is Dystrophin Activator.
Dystrophin Pipeline Drugs Market Segmentation by RoA
The key routes of administration in the Dystrophin pipeline drugs market are intravenous, subcutaneous, intramuscular, and parenteral. Intravenous has the maximum number of pipeline products.
Dystrophin Pipeline Drugs Market Analysis, by RoA
To get more insights on key RoA, download a free sample report
Key Molecule Types in the Dystrophin Pipeline Drugs Market
The key molecule types in the Dystrophin pipeline drugs market are Antisense Oligonucleotide, Gene Therapy, Cell Therapy, Antisense Gene Therapy, Monoclonal Antibody Conjugated, Gene-Modified Cell Therapy, Oligonucleotide, and Protein.
Dystrophin Pipeline Drugs Market, by Molecule Type
To get more insights on key molecule types, download a free sample report
Major Companies in the Dystrophin Pipeline Drugs Market
The major companies in the Dystrophin pipeline drugs market are Sarepta Therapeutics Inc, Astellas Gene Therapies, Avidity Biosciences Inc, Daiichi Sankyo Co Ltd, Dystrogen Therapeutics SA, Editas Medicine Inc, Nippon Shinyaku Co Ltd, NS Pharma Inc, OliPass Corporation, Pepgen Ltd, Pfizer Inc, and RegenxBio Inc.
Dystrophin Pipeline Drugs Market, by Major Companies
For more company insights, download a free sample report
Dystrophin Pipeline Drugs Market Overview
| Key Therapy Areas | Genetic Disorders, and Musculoskeletal Disorders |
| Key Mechanisms of action | Dystrophin Activator |
| Key Routes of Administration | Intravenous, Subcutaneous, Intramuscular, and Parenteral |
| Key molecule types | Antisense Oligonucleotide, Gene Therapy, Cell Therapy, Antisense Gene Therapy, Monoclonal Antibody Conjugated, Gene-Modified Cell Therapy, Oligonucleotide, and Protein |
| Major companies | Sarepta Therapeutics Inc, Astellas Gene Therapies, Avidity Biosciences Inc, Daiichi Sankyo Co Ltd, Dystrogen Therapeutics SA, Editas Medicine Inc, Nippon Shinyaku Co Ltd, NS Pharma Inc, OliPass Corporation, Pepgen Ltd, Pfizer Inc, and RegenxBio Inc |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Dystrophin
- The pipeline guide reviews pipeline therapeutics for Dystrophin by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Dystrophin therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Dystrophin therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Dystrophin
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with a potentially strong product portfolio and create effective countercstrategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Dystrophin
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Dystrophin pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Key Players
Table of Contents
List of Tables
List of Figures
Frequently Asked Questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 (0) 20 7947 2960
GDPR + CCPA Compliant
Personal and transaction information are kept safe from unauthorised use.
Recently Viewed Reports
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.